These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes. Bakhai A; Hill RA; Dundar Y; Dickson R; Walley T Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004588. PubMed ID: 15674954 [TBL] [Abstract][Full Text] [Related]
4. Coronary artery stents: a rapid systematic review and economic evaluation. Hill R; Bagust A; Bakhai A; Dickson R; Dündar Y; Haycox A; Mujica Mota R; Reaney A; Roberts D; Williamson P; Walley T Health Technol Assess; 2004 Sep; 8(35):iii-iv, 1-242. PubMed ID: 15361315 [TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stents: a systematic review and economic evaluation. Hill RA; Boland A; Dickson R; Dündar Y; Haycox A; McLeod C; Mujica Mota R; Walley T; Bagust A Health Technol Assess; 2007 Nov; 11(46):iii, xi-221. PubMed ID: 17999841 [TBL] [Abstract][Full Text] [Related]
6. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Babapulle MN; Joseph L; Bélisle P; Brophy JM; Eisenberg MJ Lancet; 2004 Aug 14-20; 364(9434):583-91. PubMed ID: 15313358 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507 [TBL] [Abstract][Full Text] [Related]
8. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Valgimigli M; Frati G; Kedhi E; Smits PC; Kaiser C; Genereux P; Galatius S; Kirtane AJ; Stone GW J Am Coll Cardiol; 2013 Aug; 62(6):496-504. PubMed ID: 23747778 [TBL] [Abstract][Full Text] [Related]
10. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419 [TBL] [Abstract][Full Text] [Related]
11. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G; JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420 [TBL] [Abstract][Full Text] [Related]
12. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis. Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ; JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063 [TBL] [Abstract][Full Text] [Related]
14. Drug eluting stents for the treatment of bare metal in-stent restenosis: long-term outcomes in real world practice. Appleby CE; Khattar RS; Morgan K; Clarke B; Curzen N; Neyses L; Fath-Ordoubadi F EuroIntervention; 2011 Jan; 6(6):748-53. PubMed ID: 21205600 [TBL] [Abstract][Full Text] [Related]
15. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925 [TBL] [Abstract][Full Text] [Related]
16. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials. Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145 [TBL] [Abstract][Full Text] [Related]
17. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202 [TBL] [Abstract][Full Text] [Related]
18. Retrospective Study of First-Generation Drug-Eluting Stents, Second-Generation Drug-Eluting Stents and Non-Drug Eluting Stent Methods in the Treatment of Native Vessel In-Stent Restenosis in Real-World Clinical Practice. Yates DJ; Savage ML; Walters DL; Raffel OC Heart Lung Circ; 2016 Apr; 25(4):342-51. PubMed ID: 26530435 [TBL] [Abstract][Full Text] [Related]
19. Drug-eluting coronary stents: many meta-analyses, little benefit. Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727 [TBL] [Abstract][Full Text] [Related]